COMMUNIQUÉS West-GlobeNewswire

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
20/04/2026
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: [...]
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
20/04/2026
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach $1.62 billion by 2030 [...]
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
20/04/2026
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in [...]
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20/04/2026
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational [...]
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
20/04/2026
PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non [...]
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
20/04/2026
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the [...]
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical- [...]
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
20/04/2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Omega Laboratories to Host Educational Panels and Present Cannabix Marijuana Breath Test Solution at the 2026 NDASA Conference in California
20/04/2026
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
20/04/2026
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance [...]
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
20/04/2026
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-dependent and [...]
Novo Nordisk A/S - share repurchase programme
20/04/2026
Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
20/04/2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, [...]
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
20/04/2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, [...]
ENvue Medical Announces 40th U.S. Hospital Customer with Addition of a Virginia Medical Center Affiliated with the Mayo Clinic Care Network
20/04/2026
Regional hospital transitions feeding tube procedures from interventional radiology to bedside nursing care using the ENvue™ Navigation Platform TYLER, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . ( [...]
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
20/04/2026
Second candidate from Tenvie’s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV108 in healthy volunteers Preliminary data expected in the [...]
Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve
20/04/2026
Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global [...]
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
20/04/2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
20/04/2026
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time, reductions in “Off [...]

Pages